Alkermes | Results Presentation Deck | 17 slides

Alkermes · 2023-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

17
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Setup
02
front_matter
Open slide detailBeat · Setup
03
transition
Open slide detailBeat · Setup
04
Includes footnotes explaining the impact of Janssen arbitration on financial results.analyze_data
Open slide detailBeat · Setup
05
Includes footnotes regarding arbitration and product definitions.analyze_data
Open slide detailBeat · Key Performance Indicator Overview
06
The table includes a blue box highlighting the Q2 2023 column. Footnotes explain the impact of an arbitration settlement on Manufacturing & Royalty Revenue.analyze_data
Open slide detailBeat · Key Performance Indicator Overview
07
Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.analyze_data
Open slide detailBeat · Key Performance Indicator OverviewLoop · Cost Of Inaction
08
front_matter
Open slide detailBeat · Key Performance Indicator OverviewLoop · Cost Of Inaction
09
The chart illustrates revenue diversification across four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.analyze_data
Open slide detailBeat · Key Performance Indicator OverviewLoop · Cost Of Inaction
10
The chart displays both weekly data and a 4-week rolling average.analyze_data
Open slide detailBeat · Key Performance Indicator OverviewLoop · Cost Of Inaction
11
summarize
Open slide detailBeat · Key Performance Indicator OverviewLoop · Cost Of Inaction
12
The chart includes a vertical dashed line separating historical data from the most recent quarter.analyze_data
Open slide detailBeat · Key Performance Indicator Overview
13
analyze_data
Open slide detailBeat · Key Performance Indicator Overview
14
appendix
Open slide detailBeat · Appendix
15
analyze_data
Open slide detailBeat · Appendix
16
The table includes specific line items for share-based compensation, depreciation, amortization, separation expenses, tax effects, non-cash interest, and a signanalyze_data
Open slide detailBeat · Appendix
17
closing_ask
Open slide detailBeat · Closing Ask